

# The effect of nutritional supplementation on retinal function

<b>Submission date</b> 21/09/2009	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 01/10/2009	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 12/04/2017	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mrs Emma Berrow

**Contact details**  
Aston University  
Aston Triangle  
Birmingham  
United Kingdom  
B4 7ET

## Additional identifiers

## Study information

**Scientific Title**  
The effect of nutritional supplementation on retinal function: a randomised controlled trial

**Study objectives**  
Nutritional supplementation may have an effect on retinal function. A randomised controlled trial comparing those taking a nutritional supplement with a control group.

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**

Aston University Ethics Committee, 01/10/2008, ref: REG/06/288[1]

**Study design**

Single-blind single-centre randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Quality of life

**Health condition(s) or problem(s) studied**

Age-related macular disease

**Interventions**

Nutritional supplement (oral) containing vitamin C 150 mg, vitamin E 15 mg, lutein 12 mg, zeaxanthin 0.6 mg, copper 400 µg, zinc 20 mg, omega-3 fatty acids 1,080 mg per day for 80 weeks.

Control group: no interventions (no placebo used)

**Intervention Type**

Supplement

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Vitamin C, vitamin E, lutein, zeaxanthin, copper, zinc, omega-3 fatty acids

**Primary outcome(s)**

Multifocal electroretinogram amplitudes and latencies, assessed every 20 weeks for a period of 80 weeks

**Key secondary outcome(s)**

Macular pigment optical density, assessed every 20 weeks for a period of 80 weeks

**Completion date**

31/12/2011

**Eligibility****Key inclusion criteria**

All participants (both males and females) must be aged 18 - 80 years.

1. For early age-related maculopathy (ARM) group in either eye or both eyes:

1.1. Drusen

1.2. Drusen with hyperpigmentation

1.3. Drusen with hypopigmentation

2. For early age-related maculopathy (ARM) group and normal group in either eye or both eyes:
- 2.1. Best corrected visual acuity of 6/9 or better
  - 2.2. Good central fixation (necessary for the multifocal electroretinogram [mfERG])
  - 2.3. Clear optical media
  - 2.4. No signs of other retinal or optic nerve disease
  - 2.5. Good general health
  - 2.6. No medication that affects the retina

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

80 years

**Sex**

All

**Key exclusion criteria**

1. Moderate to dense lens opacities
2. Intraocular lens
3. Corneal opacities
4. Glaucoma or ocular hypertension
5. Previous history of intraocular inflammation (e.g. uveitis)
6. Previous history of retinal detachment
7. Retinal disease
8. Previous retinal laser
9. Diabetes
10. Systemic hypertension
11. History of ocular trauma
12. Neurological disease
13. Advanced age-related macular disease (choroidal neovascularisation [CNV] or geographic atrophy [GA]) in the studied eye
14. Drugs causing retinal toxicity (chloroquine, cisplatin, oxazepam, vigabatrin)
15. Previous ocular surgery (excluding laser-assisted in situ keratomileusis [LASIK]/endothelial keratoplasty [EK])
16. Epilepsy

**Date of first enrolment**

01/01/2009

**Date of final enrolment**

31/12/2011

## Locations

### Countries of recruitment

United Kingdom

England

### Study participating centre

**Aston University**

Birmingham

United Kingdom

B4 7ET

## Sponsor information

### Organisation

Bausch and Lomb (UK)

### ROR

<https://ror.org/0560gb543>

## Funder(s)

### Funder type

Industry

### Funder Name

Bausch and Lomb (UK)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration